Eton Pharmaceuticals has announced promising results from its pivotal clinical study of ET-600, a proprietary oral solution of desmopressin for treating central diabetes insipidus (CDI). The study confirmed bioequivalence to the existing FDA-approved reference drug, setting the stage for regulatory submission and potential market entry.

Breakthrough for Central Diabetes Insipidus Treatment

CDI is a rare condition that affects the body’s ability to regulate water balance, leading to excessive thirst and urination. Desmopressin, a synthetic hormone, is a primary treatment option. However, no FDA-approved oral liquid formulation of desmopressin currently exists—making ET-600 a potential game-changer, particularly for pediatric patients who require precise dosing.

Clinical Study Validates ET-600’s Efficacy

The clinical study enrolled 75 healthy subjects in a randomized, three-way crossover trial to assess the pharmacokinetic equivalence of ET-600 to an existing desmopressin formulation. Results confirmed that ET-600 met bioequivalence standards, demonstrating the same absorption and effectiveness as the reference drug.

With these results, Eton plans to submit a New Drug Application (NDA) to the FDA in April 2025. If approved, ET-600 would become the first FDA-approved oral liquid desmopressin, providing a more accessible and customizable treatment for CDI patients.

Eton Pharmaceuticals: A Leader in Rare Disease Treatments

Eton Pharmaceuticals specializes in developing and commercializing therapies for rare diseases. The company currently markets seven FDA-approved rare disease drugs, including ALKINDI SPRINKLE® and INCRELEX®, and has four additional product candidates in late-stage development.

CEO Sean Brynjelsen emphasized the importance of this milestone, highlighting the significant need for a desmopressin formulation that allows precise dose adjustments, particularly for children. With an expected market launch in early 2026, ET-600 could fill this critical gap in treatment options.

What’s Next for ET-600?

Following the anticipated NDA submission in April 2025, Eton has already begun commercial readiness activities, preparing for a potential Q1 2026 market launch. The company holds a patent for ET-600’s formulation extending to 2044, reinforcing its position as a long-term player in rare disease therapies.

As Eton moves forward with regulatory approval, ET-600 represents a significant advancement in CDI treatment, offering new hope to patients and healthcare providers seeking safer and more effective solutions.

For more details, visit Eton Pharmaceuticals.